Bruker & SISCAPA Assay Technologies Announce Joint Publication on SISCAPA-MALDI-TOF Mass Spectrometry for Biomarker Validatio...
January 27 2012 - 6:00AM
Business Wire
Bruker Corporation and SISCAPA Assay Technologies, Inc. (SAT)
today announced the publication of a study in the Journal of
Proteome Research (J. Proteome Res., Just Accepted Manuscript, DOI:
10.1021/pr201092v, Publication Date (Web): January 18, 2012)
demonstrating that SISCAPA MALDI-TOF mass spectrometry provides
excellent precision for quantitation of proteins of interest, such
as high value protein biomarkers. The publication results from an
ongoing collaboration between Bruker and SAT to develop MALDI-TOF
as a high precision and high throughput mass spectrometric
detection method for SISCAPA (Stable Isotope Standards and Capture
by Anti-Peptide Antibodies) assays.
Leigh Anderson, President and CEO of
SISCAPA Assay Technologies, Inc. (Photo: Business Wire)
The collaboration aims to exploit the high throughput,
robustness and ease of use of MALDI-TOF instruments as an
alternative to nano-LC-MS technology currently used in many SISCAPA
assays. While the ease of use and robustness of MALDI-TOF make it
attractive for high throughput biomarker validation and
pre-clinical studies, MALDI-TOF has generally been considered to
have insufficient quantitative precision to be used in most
clinical biomarker assays. In recent years, however, MALDI-TOF
technology has advanced dramatically with high repetition rate
lasers (up to 1 kHz) and automated self cleaning ion sources,
resulting in faster, 24/7 operation with consistent results.
As shown in the paper published in the Journal of Proteome
Research, the use of internal, isotopically labeled peptide
standards in the SISCAPA assay yields very precise relative
quantitation of peptides (CVs of 1-2%), comparing favorably with
results obtained by the best conventional nano-LC-MS workflows. The
elimination of complex and time-consuming nano-flow LC-MS
separation greatly decreases the complexity of sample handling and
sample introduction, which, together with advances in automated
preparation of MALDI target plates, enables large scale biomarker
verification studies currently considered impractical. The
published results were obtained using a high- performance Bruker
autoflex speed MALDI-TOF mass spectrometer, and unpublished
results further indicate that assays for medium and high abundance
proteins also are possible on the benchtop microflex
MALDI-TOF used in Bruker’s MALDI Biotyper solution in
clinical microbiology, and aimed at clinical and GMP
environments.
Leigh Anderson, Ph.D., the CEO and founder of SISCAPA Assay
Technologies, and inventor of SISCAPA, commented: “We are delighted
to be working with Bruker, the leader in MALDI-TOF technology, to
advance the precision and throughput of SISCAPA biomarker assays.
Our joint paper demonstrates the very high precision of MALDI-TOF
for peptide quantitation using internal standards, and establishes
a solid basis for further exploring the utility of SISCAPA
MALDI-TOF in biomarker verification and preclinical research. As a
company devoted to the development and application of SISCAPA
assays, we are excited that the addition of this robust and easy
MALDI-TOF workflow to SISCAPA will not only increase the
productivity of labs using SISCAPA, but also increase the adoption
of SISCAPA assays by the biomarker research community.”
Dr. Detlev Suckau, Director of Proteomics at Bruker Daltonics,
added: “The results of the joint work prove that MALDI-TOF is very
suitable for peptide and protein quantification in the 1-5 % CV
range, if done properly. This is a very positive development, as
previously many proteomics researchers may have considered
MALDI-TOF as primarily a qualitative or semi-quantitative platform.
We are very pleased to continue to work with Leigh Anderson and
SISCAPA Assay Technologies on these ground-breaking biomarker
quantification and validation developments. The results in this
publication suggest that the use of the ‘LC-free’ SISCAPA-MALDI-TOF
workflow in pre-clinical research is quite attractive. This is an
emerging market for Bruker that will further increase the
visibility of our very successful MALDI-TOF product line in
biomedical research.”
About SISCAPA Assay Technologies, Inc.
SISCAPA Assay Technologies (SAT) is focused on creating SISCAPA®
assays for a growing menu of high-value protein biomarkers, with
the long-term goal of enabling sensitive, precise, high-throughput
measurement of every human protein in clinical and other samples.
Additional information about SISCAPA affinity-MS technology,
available reagents, and licensing opportunities is available at
www.SISCAPA.com.
About Bruker Corporation
Bruker Corporation (NASDAQ: BRKR) is a leading provider of
high-performance scientific instruments and solutions for molecular
and materials research, as well as for industrial and applied
analysis. For more information, please visit www.bruker.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50145886&lang=en
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024